Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies

Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Shehab, Mohammad, Alrashed, Fatema, Alfadhli, Ahmad, Alotaibi, Khazna, Alsahli, Abdullah, Mohammad, Hussain, Cherian, Preethi, Al-Khairi, Irina, Alphonse Thanaraj, Thangavel, Channanath, Arshad, Ali, Hamad, Abu-Farha, Mohamed, Abubaker, Jehad, Al-Mulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705736/
https://www.ncbi.nlm.nih.gov/pubmed/34960217
http://dx.doi.org/10.3390/vaccines9121471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705736/
https://www.ncbi.nlm.nih.gov/pubmed/34960217
http://dx.doi.org/10.3390/vaccines9121471

Ejemplares similares